Compare Amylx Pharmaceuticals Inc (AMLX) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Materials Select Sector SPDR Fund — how do they compare? Amylx Pharmaceuticals Inc trades at $17.28 (market cap $1.98B), while Materials Select Sector SPDR Fund trades at $50.72. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Materials Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| AMLX | XLB | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | — |
52-Week High | $18.70 | $53.62 |
52-Week Low | $7.64 | $42.23 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
XLB, the State Street Materials Select Sector SPDR ETF, trades at $50.89 with a 1.21% daily gain. Technical indicators signal a bearish trend with moving averages showing sell pressure, while oscillators remain neutral. Recent news highlights materials sector capital inflows and geopolitical impacts on supply chains. The ETF provides diversified exposure to U.S. materials companies, with a dividend scheduled for June 2026.
Outlook remains cautious due to bearish technicals and geopolitical sensitivity. Investment appeal hinges on sector earnings growth potential amid inflation and supply disruptions. Key risks include macroeconomic volatility and concentrated sector exposure, requiring careful risk assessment for equity investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
